A research team in a laboratory discussing the results of a lab screening test for biomarkers. Exact Sciences Corporation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the succ ...

Advancements in the key pipeline programs are highly promising. The stock carries a Zacks Rank #2 (Buy) currently. Exact Sciences is focusing on three areas to enhance its flagship Cologuard’s ...

It has been about a month since the last earnings report for Exact Sciences (EXAS ... Screening revenues, including laboratory service revenues from Cologuard and PreventionGenetics, totaled ...

Exact Sciences has a multipronged approach to cancer ... which launched in 2022 as a lab-developed test. This liquid-based single cancer detection test has lower sensitivity compared with ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

On Monday, Exact Sciences (NASDAQ:EXAS) Corporation (NASDAQ:EXAS) shares received a reaffirmed Buy rating and a steady price target of $75 from Canaccord Genuity. The endorsement comes following ...